Colorectal Cancer
Conditions
Brief summary
To assess the efficacy and safety of the combination of capecitabine and oxaliplatin in the 1st, 2nd or subsequent line treatment of metastatic colorectal cancer, and also in the neo-adjuvant and adjuvant setting of resectable metastases. Primary Endpoint: Objective response rates Secondary Endpoints: Treatment related toxicity Progression free survival (If not resected) Disease free Survival (From metastastectomy, if resected) Overall Survival 60 Day all cause mortality Number undergoing liver resections/curative resection (Ro) rate
Interventions
Sponsors
Royal Marsden NHS Foundation Trust
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>18 * Histologically proven colorectal adenocarcinoma, requiring therapy as defined by one of the four treatment subgroups * No previous malignant disease other than non-melanotic skin cancer or carcinoma-in-situ of the uterine cervix. * Unidimensional measurable disease as assessed by CT. (Unless adjuvant therapy only) * Adequate bone marrow function; Hb \>10g/dl, platelets \>100 x109/l, WBC \>3x109/l, Neut \>1.5x109/l. * Adequate liver function: Serum Bilirubin \<1.5 x upper limit of institutional normal * Adequate renal function, calculated Creatinine Clearance \>50mls/min * No concurrent uncontrolled medical conditions * WHO performance status 0,1 or 2 * Adequate contraceptive precautions, if appropriate * Informed written consent * Negative pregnancy test in women of child bearing age * Life expectancy \> 3 months
Exclusion criteria
* Medical or psychiatric condition that comprise the patient's ability to take informed consent. * Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia even if controlled with medication) or myocardial infarction within the last 12 months. * Patients with any significant symptoms or history of peripheral neuropathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rates | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival (If not resected) | — |
| Disease free Survival (From metastastectomy, if resected) | — |
| Treatment related toxicity | — |
| 60 Day all cause mortality | — |
| Number undergoing liver resections/curative resection (Ro) rate | — |
| Overall Survival | — |
Countries
United Kingdom
Outcome results
None listed